Clinical and Laboratory Investigations
Kenogen in Female Androgenetic Alopecia
Guarrera M. · Rebora A.
A Longitudinal Study
Department of Endocrinological and Metabolic Sciences, Section of Dermatology, University of Genoa, Genoa, Italy
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: Kenogen indicates the physiological interval of the hair cycle in which the hair follicle remains empty after the telogen hair has been extruded and before a new anagen hair emerges. Kenogen frequency and duration are greater in men and women with androgenetic alopecia (AGA). Objective: To study the relationship of kenogen with female AGA. Methods: A woman with AGA, studied 14 years before, was re-examined for 2 years by the phototrichogram technique. Kenogen was identified when telogen lasted 3 months and shedding left the follicle empty. Results: Kenogen lasted 1–5 months, the longest duration affecting cycles of vellus hairs, and involved more hair follicles (16 vs. 8%) than in the first observation. Cycles of vellus hairs increased in number from 4 to 13%, and cycles with a normal succession of phases decreased from 60 to 32%. Conclusions: The number of kenogen phases increased in parallel with vellus hairs and the diminished number of normal hair cycles, features that mark AGA aggravation. Kenogen seems to be related also to the progression of female AGA.
© 2005 S. Karger AG, Basel
- Rebora A, Guarrera M: Kenogen: A new phase of the hair cycle? Dermatology 2002;205:108–110.
- Rebora A, Guarrera M: Teloptosis and kenogen: Two new concepts in trichology. Arch Dermatol 2004;140:619–620.
- Piérard-Franchimont C, Piérard GE: Teloptosis, a turning point in hair shedding biorhythms. Dermatology 2001;203:115–117.
- Paus R: Principles of hair cycle control. J Dermatol 1998;25:793–802.
- Guarrera M, Rebora A: Anagen hairs may fail to replace telogen hairs in early androgenetic female alopecia. Dermatology 1996;192:28–31.
Guarrera M, Ciulla MP: A quantitative evaluation of hair loss: The phototrichogram. J Appl Cosmetol 1986;4:61–66.
- Van Neste DJ, de Brouwer B, de Coster W: The phototrichogram: Analysis of some technical factors of variation. Skin Pharmacol 1994;7:67–72.
Whiting DA: Possible mechanisms of miniaturization during androgenetic alopecia or pattern hair loss. J Am Acad Dermatol 2001;45(suppl 3):S81–S86.
- Courtois M, Loussouarn G, Hourseau C, Grollier JF: Hair cycle and alopecia. Skin Pharmacol 1994;7:84–89.
- Birch MP, Lalla SC, Messenger AG: Female pattern hair loss. Clin Exp Dermatol 2002;27:383–388.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.